Innovative Cellular Therapeutics Holdings Ltd - Nov 6, 2025 SCHEDULE 13G Report for Lyell Immunopharma, Inc. Common Stock, par value $0.0001 (LYEL)

Filing Manager: Innovative Cellular Therapeutics Holdings Ltd
Reporting Manager: Innovative Cellular Therapeutics Holdings Ltd
Security: Lyell Immunopharma, Inc. Common Stock, par value $0.0001
Symbol: LYEL
Shares outstanding: 19.4M shares
Disclosed Ownership: 1.9M shares
Ownership: 9.8%
Form type: SCHEDULE 13G
Date filed: 11/13/2025, 05:04 PM
Date of event: Nov 6, 2025
SEC: View on sec.gov

Reporting Managers (1)

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title	CIK
Innovative Cellular Therapeutics Holdings Ltd	9.8%	1.9M	1.9M	0	/s/ Lei Xiao	Lei Xiao/ Chief Executive Officer